Navigation Links
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Date:10/19/2009

red with an increase of 1.37 (+/- 4.56) score in the group receiving placebo plus methotrexate (P<0.015). The reduction in progression of vdH-S scores seen with the 50 mg and 100 mg doses was comparable.

In a second study, the GOlimumab FOR subjects With Active RA Despite Methotrexate (GO-FORWARD) clinical trial, vdH-S changes from baseline were minimal in all groups studied (including the placebo arm) which prevented any significant effect of SIMPONI to be detected. A lack of progression in the placebo group may have been due to the short placebo-controlled period of the trial and relatively less active patient population than in previously reported RA trials.

Psoriatic Arthritis

In the Golimumab - A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL) trial, patients with active PsA receiving SIMPONI 50 mg showed significantly less progression of structural damage at week 24 compared with patients receiving placebo plus methotrexate, and the benefit was maintained through 52 weeks. Structural damage was measured using the vdH-S score. The mean change (+/- standard deviation) from baseline in patients receiving SIMPONI was a decrease of 0.16 (+/- 1.31) score at week 24 compared with an increase of 0.27 (+/- 1.26) score in the placebo group (P=0.011). At week 24 all placebo patients began receiving SIMPONI 50 mg. At week 52, the mean change from baseline in total vdH-S score was -0.22 (+/- 1.64) in patients initially randomized to SIMPONI 50 mg at baseline while the mean score in the group who crossed over from placebo to SIMPONI at week 24 was 0.22 (+/- 1.38).

"Results from the GO-REVEAL study show that treatment with golimumab inhibited joint destruction in patients with active psoriatic arthritis," said Dr. Arthur Kavanaug
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
2. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd
4. Nanosyn, Inc. and PCAS Announce the Signing of a Joint-Venture Agreement to Operate PCAS-NANOSYN, LLC
5. ClinfoSource and California State University, East Bay Jointly Launch On-Line Certificate Program in Clinical Research
6. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
7. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
8. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
9. NIH funds support UAB joint replacement research
10. Health Robotics Expands and Diversifies Global Channel Strategies With Joint-Ventures & Direct Operations
11. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... John Wagner, M.D., recognized as,a leader in the field ... at CORD:USE Cord Blood Bank. Dr. Wagner,s extensive experience ... provide a,significant contribution to CORD:USE., "We,re honored and ... team," says Edward Guindi, M.D., President and CEO of,CORD:USE ...
... To Draw Attention To ,The Sneak Thief of Sight, ... to combat one of the,main causes of blindness around ... Patient Organization have announced the first annual,World Glaucoma Day, ... will be marked,by awareness and educational events organized by ...
... In,conjunction with QIAGEN,s Fourth Quarter and Year End 2007 Earnings,release, ... be,broadcast live over the Internet on Tuesday, February 12, 2008 at ... and Roland,Sackers, Chief Financial Officer., What: ... and ...
Cached Biology Technology:CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3World Glaucoma Day Set for March 6th 2QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web 2
(Date:7/8/2015)... , July 8, 2015 The ... as this summer,s must have products such as wearables, smart ... as popularity for biometrics based devices continues to rapidly grow.  ... Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and ...
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... one of the detrimental effects of climate change, may receive ... research by a team of scientists recording the long-term recovery ... that coral reefs are very resilient and can bounce back ... or so of pristine conditions," says Robert van Woesik, one ...
... baby is doing what other babies her age are doing ... she loves to dance." , Lolita Harding is describing her ... large part to a thymus transplant she received at Duke ... immune system. Dave'yana was the 31st baby to receive such ...
... did the hearing of dinosaurs compare to that of present-day ... conditions in office cubicles" How can sound waves diagnose ... be addressed at the 153rd Meeting of the Acoustical Society ... 2007 in Salt Lake City. Most sessions will be ...
Cached Biology News:Palau's coral reefs show differential habitat recovery following the 1998 bleaching event 2Thymus transplants gives hope to babies with fatal immune disease 2Thymus transplants gives hope to babies with fatal immune disease 3Dinosaur hearing, listening to muscle noise, quieter cubicles 2Dinosaur hearing, listening to muscle noise, quieter cubicles 3Dinosaur hearing, listening to muscle noise, quieter cubicles 4Dinosaur hearing, listening to muscle noise, quieter cubicles 5Dinosaur hearing, listening to muscle noise, quieter cubicles 6Dinosaur hearing, listening to muscle noise, quieter cubicles 7Dinosaur hearing, listening to muscle noise, quieter cubicles 8Dinosaur hearing, listening to muscle noise, quieter cubicles 9Dinosaur hearing, listening to muscle noise, quieter cubicles 10Dinosaur hearing, listening to muscle noise, quieter cubicles 11Dinosaur hearing, listening to muscle noise, quieter cubicles 12Dinosaur hearing, listening to muscle noise, quieter cubicles 13
...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... formulated for covering tissue sections and cell preparations ... alcohol insoluble end products. UltraMount Plus ... Red or AEC that require an aqueous mounting ... DAB. No heating is required prior to use. ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: